Organic Chemistry TRIZ Cases

A metal-salt-catalyzed oxidative ring closure replaces corrosive routes for scalable, high-purity benzotriazole production.

Phenanthryl compounds improve charge transport and recombination in organic EL devices.

Imidazolo indazole compounds provide localized JAK inhibition for severe asthma and CLAD while reducing systemic immunosuppression risk.

This case combines heteroatom and aromatic molecular design to improve OLED driving voltage, efficiency, stability, and lifetime.

Explore BRD9-degrading compounds that reduce SS18-SSX in synovial sarcoma while modulating antiviral defense tradeoffs.

Replacing the gas before cooling bypasses liquid formation, reducing evacuation energy and thermal bridges in the vessel.

Defect-engineered UiO-66-based Zr-MOF catalyzes CO2–epoxide conversion, simplifying recovery while delivering 40–97% yields.

A spiro OLED emitter uses delayed fluorescence and reduced molecular association to improve luminous efficiency and driving durability.

This case uses Formula (I) bicyclic compounds to target HBV cccDNA, inhibit HBV and HDV replication, and reduce liver disease risk.

Pre-functionalized ADAMS monomers form copolymers for low-viscosity oils with wear protection, soot handling, and cleanliness.

This case combines sequential reactions with dimethylacetamide-alcohol crystallization to limit impurities in crystalline relugolix.

Deuterium-substituted compounds lower OLED voltage and improve efficiency.

This case develops Mavacamten Form 7, a non-hygroscopic polymorph resistant to humidity, heat, and mechanical stress.

A specific triazine structure helps balance crystallinity and transparency in polyolefin resin molded objects.

This Valsartan process combines sodium hydrosulfite reduction and activated-charcoal treatment to meet USFDA and EMEA purity standards.

This case uses selective polymeric inhibition of SHC-1/p66 to reduce ROS, cellular degeneration, and motor deficits.

This case uses substituted 8-hydroxyquinoline compounds to improve KDM4 activity and selectivity for treating diverse cancers.

This case examines imidazole compounds that modulate PERK, IRE1, and ATF6 pathways to rescue stressed cells in autoimmune therapy.

This case shows how isoquinoline compounds inhibit HPK1 to enhance immunity while addressing healthy-cell damage and treatment resistance.

This case uses VDAC1/VDAC2 modulation to enhance mitochondrial Ca2+ uptake and reduce arrhythmogenic events.

Coarse screening protects a fine membrane as it removes poly(propylene oxide) from propylene oxide to below 1 ppm.

This case addresses aqueous instability in multi-aziridine crosslinkers with a pH-controlled dispersion for stable, low-viscosity coatings.

This case uses 2–6 linked aziridine units and an 840–5000 Dalton range to crosslink polymers with lower genotoxicity.

This case develops single-bonded organic molecules with TADF and 20%+ quantum yields for stable blue-to-green OLED emission.

This case uses modular chemical structure changes to improve YAP/TAZ-TEAD inhibition, pharmacokinetics, and therapeutic tolerability.

Bis-aryl sulfonamide ERAP1 modulators fine-tune peptide trimming, helping preserve neoantigen presentation for cancer immunotherapy.

This process combines staged Grignard reaction, hydrolysis, and recrystallization to improve lasmiditan and hemisuccinate purity.

Quinoline-based compounds selectively inhibit PFKFB4, reduce F2,6BP and glycolysis, and support orally bioavailable cancer treatment.

This case develops oxopyridine derivatives that inhibit ACMSD, addressing lack of effective inhibitors and increasing intracellular NAD+.

This case uses heteroaryl substitutions on oseltamivir to inhibit resistant influenza strains while preserving oral bioavailability.

This case uses β2-adrenergic agonists to support insulin-independent muscle glucose uptake while limiting cAMP-mediated adverse effects.

This case replaces toxic metal catalysts with malic acid-rich apple juice for safer, sustainable pyrrole synthesis under mild conditions.

This case uses orally bioavailable heterocyclic compounds to inhibit TLR8/9 signaling and reduce pro-inflammatory cytokine expression.

A modified acid-mediated route forms diaryl triazine intermediates with fewer impurities for purer UV absorber synthesis.

A high-glass-transition heterocyclic compound blocks hole diffusion, balances OLED transport, and extends device service life.

Triazolopyrimidine compounds selectively inhibit NAE to regulate CRL activity and support tumor treatment with fewer broad UPS effects.

This case uses PKR activators and metabolic intermediaries to stabilize red cells, increase oxygen affinity, and treat hemolytic anemia.

A Formula I organic emitter combines donor and acceptor groups to tune OLED color while improving emission efficiency.

Sodium bicarbonate and methanol form a ring-opened intermediate before Raney nickel hydrogenation, supporting catalyst reuse.

A refractive-index-engineered hole transporting zone improves light extraction and luminous efficiency in organic EL devices.

This case examines pyrimidine compounds that address slow GTP hydrolysis by stabilizing KRAS G12D in an inactive state.

Sequential intermediates and coupling steps prepare a covalent inhibitor that disrupts the menin-MLL interaction.

Benzylindazole compounds activate heme-dependent sGC and cGMP synthesis, supporting smooth muscle relaxation and vasodilation.

Formula 32 polycyclic compounds in a p-type charge generation layer improve OLED charge distribution, optical loss, and lifetime.

This case examines dual A2a/A2b antagonists that restore cytotoxic immune function despite high tumor adenosine.

This resist chemistry combines EUV-absorbing iodine with localized acid generation to improve solubility, LWR, CDU, and etch resistance.

Carbazole-based and triphenylene or phenanthrene hosts balance charge transport to improve efficiency and extend device lifespan.

This EUV resist case uses fluorine-containing onium salt monomers to balance acid diffusion, sensitivity, LWR, CDU, and etch resistance.

This case targets the 3βHSD1 step converting androstenedione to active androgens, addressing resistance in prostate and other cancers.

A pH-responsive ionizable lipid self-assembles with other lipids to bind antibodies or peptides and improve cellular uptake.